Search
Semaglutide Treatment Options for Type 2 Diabetes
A collection of 93 research studies in Type 2 Diabetes where Semaglutide is the interventional treatment. Semaglutide is used for conditions such as Type 2 Diabetes.
13 - 24 of 93
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Type 2 Diabetes
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Trial
Studying an Investigational Monitoring System in Adults with Type 2 Diabetes
Recruiting
The main objectives of this study are to assess the safety and effectiveness of an investigational continuous glucose monitoring system compared to routine care in adults with type 2 diabetes. Additionally, the study aims to evaluate the quality of life improvements that may come with using the investigational device. Should you express interest, you will be contacted directly by the research site, who will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.
Conditions:
All Conditions
Type 2 Diabetes (T2DM)
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Active Not Recruiting
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: University of Alabama - Department of Nutrition Sciences, Birmingham, Alabama +76 locations
Conditions: Diabetes Mellitus, Type 2
Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data
Active Not Recruiting
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction
Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction
Active Not Recruiting
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction
Triple Therapy in T1DM
Active Not Recruiting
To assess whether the addition of dapagliflozin to semaglutide and insulin (triple therapy) improves glycemic control in patients with type 1 diabetes compared with semaglutide and insulin (dual therapy) and insulin only (standard) treatment.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/31/2025
Locations: Diabetes and Endocrinology Research Center of WNY, Williamsville, New York
Conditions: Type 1 Diabetes Mellitus
ADJUnct Semaglutide Treatment in Type 1 Diabetes
Completed
The purpose of this study is to assess the use of once weekly semaglutide injection in inadequately controlled obese adults with type 1 diabetes (T1D) using FDA-approved hybrid closed-loop therapies.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/28/2025
Locations: Barbara Davis Center for Diabetes, Aurora, Colorado +3 locations
Conditions: Type 1 Diabetes, Obesity
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
Recruiting
This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active comparator.
Gender:
ALL
Ages:
All
Trial Updated:
03/24/2025
Locations: Research Site, Mobile, Alabama +119 locations
Conditions: Diabetes Mellitus, Type 2
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Active Not Recruiting
The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone. CagriSema will also be compared to a "dummy" medicine without any active ingredient. The study will be done in participants who have type 2 diabetes. Participants will take the study medicine togethe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Univ of Alabama_Birmingham, Birmingham, Alabama +346 locations
Conditions: Type 2 Diabetes Mellitus
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
Recruiting
This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesity. CagriSema is a new investigational medicine. CagriSema cannot yet be prescribed by doctors. The study will compare CagriSema to the 2 medicines semaglutide and cagrilintide, when they are taken alone. It will also compare CagriSema to a "dummy" medicine (also called placebo) without any active ingredient. Participant will either get CagriSema, se... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: John Muir Physicians Network, Concord, California +139 locations
Conditions: Chronic Kidney Disease, Type 2 Diabetes, Obesity
Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)
Completed
This study plans to learn more about the effect of semaglutide once weekly on intestinal permeability in individuals with type 2 diabetes.
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
03/17/2025
Locations: University of Colorado Anschutz, Aurora, Colorado
Conditions: Type 2 Diabetes, Chronic Inflammation, Intestinal Permeability
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
Completed
The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes. Participants will get semaglutide (active medicine) or placebo ('dummy medicine'). This is known as participants' study medicine - which treatment participants get is decided by chance. Semaglutide is a medicine, doctors can prescribe in some countries for the treatment of type 2 diabetes. Participants will get the study medicine in a pen. Pa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: Dr. Terence Hart, Tuscumbia, Alabama +412 locations
Conditions: Diabetes Mellitus, Type 2
Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes
Completed
This study compares three doses of once daily semaglutide tablets in people with type 2 diabetes who were previously treated with other oral anti-diabetic medicines. Participants will be initiated on the lowest starting dose of 3 mg and gradually increased until they reach the final trial dose of 14 mg, 25 mg or 50 mg once daily semaglutide tablets. The final three doses will be randomized (i.e., decided by chance). Participants will be administered one tablet per day for 68 weeks. Women cannot... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: American Clinical Trials, Buena Park, California +180 locations
Conditions: Diabetes Mellitus, Type 2
A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets
Completed
Participants in the study, will receive the study drug once daily for 10 days in tablet form for oral (by mouth) intake. On day 1 to 5 the tablet will contain 3 mg semaglutide, and on day 6-10 the tablet will contain 7 mg semaglutide.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: ICON Early Phase Services, LLC, San Antonio, Texas +1 locations
Conditions: Diabetes Mellitus, Type 2
13 - 24 of 93